365 related articles for article (PubMed ID: 36268462)
1. Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.
Attard LM; Gatt A; Bertoletti L; Delluc A; Riva N
Vasc Health Risk Manag; 2022; 18():793-807. PubMed ID: 36268462
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
[TBL] [Abstract][Full Text] [Related]
3. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
4. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
8. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Riaz IB; Fuentes HE; Naqvi SAA; He H; Sipra QR; Tafur AJ; Padranos L; Wysokinski WE; Marshall AL; Vandvik PO; Montori V; Bryce AH; Liu H; Badgett RG; Murad MH; McBane RD
Mayo Clin Proc; 2022 Feb; 97(2):308-324. PubMed ID: 34172290
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
[TBL] [Abstract][Full Text] [Related]
11. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
Ay C; Beyer-Westendorf J; Pabinger I
Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
Song AB; Rosovsky RP; Connors JM; Al-Samkari H
Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
[TBL] [Abstract][Full Text] [Related]
13. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
Martins MA; Silva TF; Fernandes CJ
Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
Voigtlaender M; Langer F
Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
17. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.
Bauersachs R; Khorana AA; Lee AYY; Soff G
Res Pract Thromb Haemost; 2020 May; 4(4):532-549. PubMed ID: 32548552
[TBL] [Abstract][Full Text] [Related]
19. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
Carrier M; Soff G; Le Gal G
Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
